ServiceTitan initiated, Viracta downgraded: Wall Street's top analyst calls [Yahoo! Finance]
Viracta Therapeutics, Inc. (VIRX)
Company Research
Source: Yahoo! Finance
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Rating Changes: Baird initiated coverage of ServiceTitan (TTAN) with an Outperform rating and $117 price target. Profitability will likely inflect higher as the residential and commercial repair software company expands its total addressable market, says the analyst, who adds that to the extent that revenue growth continues to track in the 20%-plus range, "we expect our investment framework to prove conservative." 86 Research upgraded Tencent Music (TME) to Buy from Hold with a $14 price target. Rodman & Renshaw downgraded Viracta Therapeutics (VIRX) to Neutral from Buy with a price target of 25c, down from $3.50, after Viracta announced it has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas to maximize its cash runway while the boar
Show less
Read more
Impact Snapshot
Event Time:
VIRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIRX alerts
High impacting Viracta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VIRX
News
- Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its "neutral" rating re-affirmed by analysts at Rodman & Renshaw. They now have a $0.25 price target on the stock, down previously from $3.50.MarketBeat
- Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives [Yahoo! Finance]Yahoo! Finance
- Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic AlternativesGlobeNewswire
- Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its price target lowered by analysts at Royal Bank of Canada from $4.00 to $2.00. They now have an "outperform" rating on the stock.MarketBeat
- Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire